Deciphera Pharmaceuticals (DCPH) Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DCPH shares.
View DCPH analyst ratings or view top-rated stocks.

9 Wall Street research analysts have issued twelve-month price targets for Deciphera Pharmaceuticals' stock. Their DCPH share price forecasts range from $9.00 to $30.00. On average, they expect the company's stock price to reach $21.78 in the next year. This suggests a possible upside of 58.5% from the stock's current price.
View analysts price targets for DCPH or view top-rated stocks among Wall Street analysts.

Deciphera Pharmaceuticals' stock was trading at $16.39 at the beginning of 2023. Since then, DCPH stock has decreased by 16.2% and is now trading at $13.74.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our DCPH earnings forecast.

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) posted its earnings results on Wednesday, May, 3rd. The company reported ($0.60) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.60). The firm earned $33.45 million during the quarter, compared to the consensus estimate of $35.50 million. Deciphera Pharmaceuticals had a negative net margin of 131.38% and a negative trailing twelve-month return on equity of 46.56%. The company's revenue for the quarter was up 14.4% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.80) EPS.

ETFs with the largest weight of Deciphera Pharmaceuticals (NASDAQ:DCPH) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP).Range Cancer Therapeutics ETF (CNCR).

3 employees have rated Deciphera Pharmaceuticals Chief Executive Officer Steve Hoerter on Glassdoor.com. Steve Hoerter has an approval rating of 100% among the company's employees. This puts Steve Hoerter in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Vertex Pharmaceuticals (VRTX), Allena Pharmaceuticals (ALNA), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Iovance Biotherapeutics (IOVA), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM) and Exelixis (EXEL).

(DCPH) raised $101 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

Deciphera Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Cibc World Markets Corp (0.38%), Bank of New York Mellon Corp (0.26%), SG Americas Securities LLC (0.19%), Barclays PLC (0.18%), Allspring Global Investments Holdings LLC (0.18%) and Allspring Global Investments Holdings LLC (0.18%). Insiders that own company stock include Brightstar Associates Llc, Daniel C Martin, Daniel Lee Flynn, Dennis Leo Walsh, Franklin Stuart Friedman, Jama Pitman, James Arthur Bristol, Matthew L Sherman, Michael Douglas Taylor, Steven L Hoerter and Thomas Patrick Kelly.
View institutional ownership trends.

Shares of DCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DCPH stock can currently be purchased for approximately $13.74.

Deciphera Pharmaceuticals (NASDAQ:DCPH) has a market capitalization of $1.08 billion and generates $134.04 million in revenue each year. The company earns $-178,930,000.00 in net income (profit) each year or ($2.35) on an earnings per share basis.

The company employs 300 workers across the globe.

Deciphera Pharmaceuticals' mailing address is 200 SMITH STREET, Waltham MA, 02451. The official website for the company is www.deciphera.com. The company can be reached via phone at (781) 209-6400 or via email at eciphera@argotpartners.com.